BEGIN:VCALENDAR VERSION:2.0 PRODID:IEEE vTools.Events//EN CALSCALE:GREGORIAN BEGIN:VTIMEZONE TZID:America/Montreal BEGIN:DAYLIGHT DTSTART:20180311T030000 TZOFFSETFROM:-0500 TZOFFSETTO:-0400 RRULE:FREQ=YEARLY;BYDAY=2SU;BYMONTH=3 TZNAME:EDT END:DAYLIGHT BEGIN:STANDARD DTSTART:20181104T010000 TZOFFSETFROM:-0400 TZOFFSETTO:-0500 RRULE:FREQ=YEARLY;BYDAY=1SU;BYMONTH=11 TZNAME:EST END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTAMP:20180606T164411Z UID:4223C541-83EA-41EE-8C28-88BD8B2C5697 DTSTART;TZID=America/Montreal:20180605T180000 DTEND;TZID=America/Montreal:20180605T210000 DESCRIPTION:IEEE MONTREAL KEYNOTE EVENT: INVENTORS AND ENTREPRENEURS\n\nAng ioplasty Balloons\, Heart Stents\, to Glaucoma Treatment: The Tools that H elped Establish Interventional Cardiology and Ophthalmology from the Persp ective of an Innovator and Entrepreneur\n\nPlease come and hear Dr. Leonar d Pinchuk's (Founder\, CEO\, NAE\, AIMBE) amazing story starting from McGi ll Chemistry student to inventor and CEO responsible for some of the most important medical interventions of our generation.\n\nDr. Pinchuk’s entr epreneurial teams of chemists and engineers have been involved in the deve lopment of the fundamental tools that changed radiology and cardiology fro m a diagnostic discipline to the therapeutic interventional radiology and cardiology that is practiced today. They introduced the first commercially successful angioplasty balloon in the mid 1980’s\, which demonstrated a success rate of 60%\, the coronary stent\, and the development of the dru g-eluting stent that improved the success rate to almost 100%. The most su ccessful drug-eluting stent (TAXUS®) uses SIBS\, a novel polymer that the y patented. The introduction of SIBS in medicine was an overwhelming succe ss that overcame many years of frustration from working with polymers that were never designed to be used in the body. The success of SIBS in the ca rdiovascular system led to the development of the InnFocus MicroShunt®\, a micro-conduit used to treat glaucoma. The MicroShunt is currently changi ng the way advanced glaucoma is treated world-wide. Similarly\, the use of a variant of SIBS is being tested as the next generation intraocular lens (IOL) material that will eliminate three of the major flaws with current IOLs and possibly the elimination of reading glasses post-cataract surgery .\n\nCo-sponsored by: McGill Faculty of Science\n\nAgenda: \n6:00-7:00 Ref reshments and Introductions\n\n7:00-9:00 Dr. Pinchuk talk and Q & A\n\nBIO GRAPHY:\n\nDr. Leonard Pinchuk is an inventor and entrepreneur with 126 is sued U.S. patents\, 80 publications and 10 companies that he co-founded. H is major accomplishments include the invention or co-invention of the mode rn-day angioplasty balloon\, the helical wire stent\, the modular stent-gr aft\, a drug-eluting stent (TAXUS®)\, three important biomaterials\, a no vel glaucoma shunt and the next generation intraocular lens material. He w as the 2017 recipient of the Society for Biomaterials Innovation and Techn ology Award as well as San Antonio’s 2017 BIOMED SA Award. He received a B.Sc. in chemistry from McGill University (1976)\, a Ph.D. interdisciplin ary in Engineering and Chemistry from the University of Miami (1984) and a n honorary Doctor of Science degree from McGill University (2005). He was inducted into AIMBE in 2007 and the National Academy of Engineering in 201 2. Dr. Pinchuk began his career in 1983 at Cordis Corporation and left in 1987 to co-found Corvita Corporation (angioplasty catheters\, stents\, st ent-grafts)\, which went public in 1994\, was acquired by Pfizer\, Inc. (1 996) and then sold to Boston Scientific (1998). Dr. Pinchuk founded Innovi a LLC (2002)\, which incubated and spun off eight new companies working in the fields of intraocular lenses\, glaucoma shunts\, other catheters and biomaterials. His current company\, InnFocus\, Inc.\, which has developed a novel treatment for glaucoma\, was acquired by Santen Corporation in May 2016\, where he is serving as CSO until 2020. Dr. Pinchuk also enjoys an appointment as Distinguished Research Professor of Biomedical Engineering at the University of Miami.\n\nRoom: 112\, Bldg: Otto Maass (Chemistry Bui lding)\, McGill University\, 801 Sherbrooke Street West\, Montreal\, Quebe c\, Canada\, H3A 2K6 LOCATION:Room: 112\, Bldg: Otto Maass (Chemistry Building)\, McGill Univers ity\, 801 Sherbrooke Street West\, Montreal\, Quebec\, Canada\, H3A 2K6 ORGANIZER:a.pinchuk@ieee.org SEQUENCE:8 SUMMARY:IEEE MONTREAL KEYNOTE EVENT: INVENTORS & ENTREPRENEURS URL;VALUE=URI:https://events.vtools.ieee.org/m/172629 X-ALT-DESC:Description: <br /><p><strong>IEEE MONTREAL KEYNOTE EVENT: INVEN TORS AND ENTREPRENEURS</strong></p>\n<p><strong>Angioplasty Balloons\, Hea rt Stents\, to Glaucoma Treatment:&nbsp\; The Tools that Helped Establish Interventional Cardiology and Ophthalmology </strong><strong>from the Pers pective of an Innovator and Entrepreneur</strong></p>\n<p><em>Please come and hear&nbsp\;Dr. Leonard Pinchuk's&nbsp\;(Founder\, CEO\, NAE\, AIMBE) a mazing story starting from McGill Chemistry student to inventor and CEO re sponsible for some of the most important medical interventions of our gene ration.</em></p>\n<p>Dr. Pinchuk&rsquo\;s entrepreneurial teams of chemist s and engineers have been involved in the development of the fundamental t ools that changed radiology and cardiology from a diagnostic discipline to the therapeutic interventional radiology and cardiology that is practiced today.&nbsp\;&nbsp\; They introduced the first commercially successful an gioplasty balloon in the mid 1980&rsquo\;s\, which demonstrated a success rate of 60%\,&nbsp\;the coronary stent\, and the development of the drug-e luting stent that improved the success rate to almost 100%.&nbsp\; The mos t successful drug-eluting stent (TAXUS&reg\;) uses SIBS\, a novel polymer that they patented.&nbsp\;The introduction of SIBS in medicine was an over whelming success that overcame many years of frustration from working with polymers that were never designed to be used in the body.&nbsp\;&nbsp\; T he success of SIBS in the cardiovascular system led to the development of the InnFocus MicroShunt&reg\;\, a micro-conduit used to treat glaucoma.&nb sp\; The MicroShunt is currently changing the way advanced glaucoma is tre ated world-wide.&nbsp\; Similarly\, the use of a variant of SIBS is being tested as the next generation intraocular lens (IOL) material that will el iminate three of the major flaws with current IOLs and possibly the elimin ation of reading glasses post-cataract surgery.</p><br /><br />Agenda: <br /><p style="margin: 0px\;"><span lang="EN-US" style="margin: 0px\;"><span style="font-family: Calibri\; font-size: medium\;">6:00-7:00 Refreshments and Introductions</span></span></p>\n<p style="margin: 0px\;"><span lang= "EN-US" style="margin: 0px\;"><span style="font-family: Calibri\; font-siz e: medium\;">7:00-9:00 Dr. Pinchuk talk and Q &amp\; A</span></span></p>\n <p><span style="color: #ff9900\; font-size: 18pt\;"><strong>BIOGRAPHY:&nbs p\;</strong></span></p>\n<p style="margin: 0px 0px 10.66px\;"><span lang=" EN-US" style="margin: 0px\;"><span style="font-family: Calibri\; font-size : medium\;">Dr. &nbsp\;Leonard Pinchuk is an inventor and entrepreneur wit h 126 issued U.S. patents\, 80 publications and 10 companies that he co-fo unded.<span style="margin: 0px\;">&nbsp\; </span>His major accomplishments include the invention or co-invention of the modern-day angioplasty ballo on\, the helical wire stent\, the modular stent-graft\, a drug-eluting ste nt (TAXUS&reg\;)\, three important biomaterials\, a novel glaucoma shunt a nd the next generation intraocular lens material.<span style="margin: 0px\ ;">&nbsp\;&nbsp\; </span>He was the 2017 recipient of the Society for Biom aterials Innovation and Technology Award as well as San Antonio&rsquo\;s 2 017 BIOMED SA Award.<span style="margin: 0px\;">&nbsp\; </span>He received a B.Sc. in chemistry from McGill University (1976)\, a Ph.D. interdiscipl inary in Engineering and Chemistry from the University of Miami (1984) and an honorary Doctor of Science degree from McGill University (2005).&nbsp\ ; He was inducted into AIMBE in 2007 and the National Academy of Engineeri ng in 2012.&nbsp\;<span style="margin: 0px\;">&nbsp\; </span>Dr. Pinchuk b egan his career in 1983 at Cordis Corporation and left in 1987 to co-found Corvita Corporation (angioplasty catheters\, stents\, stent-grafts)\, whi ch went public in 1994\, was acquired by Pfizer\, Inc. (1996) and then sol d to Boston Scientific (1998).<span style="margin: 0px\;">&nbsp\; </span>D r. Pinchuk founded Innovia LLC (2002)\, which incubated and spun off eight new companies working in the fields of intraocular lenses\, glaucoma shun ts\, other catheters and biomaterials.<span style="margin: 0px\;">&nbsp\; </span>His current company\, InnFocus\, Inc.\, which has developed a novel treatment for glaucoma\, was acquired by Santen Corporation in May 2016\, where he is serving as CSO until 2020.<span style="margin: 0px\;">&nbsp\; &nbsp\; </span>Dr. Pinchuk also enjoys an appointment as Distinguished Res earch Professor of Biomedical Engineering at the University of Miami.</spa n></span></p> END:VEVENT END:VCALENDAR